Plasma Fibrinogen at Recurrence as a Prognostic Blood Biomarker in Oral Cavity Squamous Cell Carcinoma
Diagnostics · 21.07.2026 · 16 (14) · 2276
DOI: 10.3390/diagnostics16142276 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 21.07.2026. Verfasst von Rafael Gómez-Fernández und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Surgery, Hospital Universitario Río Hortega, Calle Dulzaina 2, 47012 Valladolid, Spain. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HURH–ICSCYL (Hospital Universitario Río Hortega—Instituto de Estudios de Ciencias de la Salud de Castilla y León.
Abstract (Originalsprache)
Background
Preoperative inflammatory biomarkers, particularly the neutrophil-to-lymphocyte ratio (NLR), are established prognostic markers in oral cavity squamous cell carcinoma (OCSCC), yet their relevance at the biologically distinct timepoint of disease recurrence is unknown. We evaluated blood biomarkers measured at recurrence.
Methods
From a retrospective cohort of 168 surgically treated OCSCC patients, 70 (41.7%) developed recurrence (49 local, 21 distant). NLR, lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR), plasma fibrinogen, albumin and the prognostic nutritional index (PNI) at relapse were analysed against 5-year overall survival; multivariate logistic regression was adjusted for age and recurrence type.
Results
Forty-nine of 70 patients (70.0%) died within 5 years. Fibrinogen was higher in deceased patients (median 595 vs. 464 mg/dL; p = 0.007) and was the only biomarker to retain independent significance (OR 1.005 per mg/dL; 95% CI 1.000–1.010; p = 0.038); in contrast, NLR lost significance (p = 0.156). LMR was significant univariately (p = 0.036); PLR, albumin and PNI were not.
Conclusions
In this exploratory single-centre cohort, higher plasma fibrinogen at recurrence was independently associated with 5-year mortality, whereas inflammatory ratios were not. These hypothesis-generating findings warrant validation in larger, multicentre cohorts.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oral and Maxillofacial Surgery, Hospital Universitario Río Hortega, Calle Dulzaina 2, 47012 Valladolid, Spain.
ORCID-Profile: Rafael Gómez-Fernández, Belén Burgos-Vico
Förderung
- HURH–ICSCYL (Hospital Universitario Río Hortega—Instituto de Estudios de Ciencias de la Salud de Castilla y León
Zitieren
APA
Gómez-Fernández, R., Vallejo-Díez, J., Zarauza-Santos, B., Burgos-Vico, B., Heras-Losada, S. L., & Redondo-González, L. M. (2026). Plasma Fibrinogen at Recurrence as a Prognostic Blood Biomarker in Oral Cavity Squamous Cell Carcinoma. Diagnostics, 16(14), 2276. https://doi.org/10.3390/diagnostics16142276
Vancouver
Gómez-Fernández R, Vallejo-Díez J, Zarauza-Santos B, Burgos-Vico B, Heras-Losada SL, Redondo-González LM. Plasma Fibrinogen at Recurrence as a Prognostic Blood Biomarker in Oral Cavity Squamous Cell Carcinoma. Diagnostics. 2026;16(14):2276. doi:10.3390/diagnostics16142276
BibTeX
@article{GmezFernndez2026,
author = {Gómez-Fernández, Rafael and Vallejo-Díez, Jorge and Zarauza-Santos, Beatriz and Burgos-Vico, Belén and Heras-Losada, Sonia de Las and Redondo-González, Luis Miguel},
title = {Plasma Fibrinogen at Recurrence as a Prognostic Blood Biomarker in Oral Cavity Squamous Cell Carcinoma},
journal = {Diagnostics},
year = {2026},
volume = {16},
number = {14},
pages = {2276},
doi = {10.3390/diagnostics16142276}
}
EUVIMED